Hemo Organic accepts resignation of Company Secretary Yukta Patel

0 min read | Published on 19 Sept 2026, 08:24 PM |Updated on 19 Sept 2026, 08:24 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Hemo Organic Limited accepted the resignation of Company Secretary Yukta Prakash Patel
The departure is effective from September 19, 2026, due to personal reasons
Disclosure made under Regulation 30 of SEBI LODR Regulations 2015
No material reasons for resignation cited other than personal factors

*this image is generated using AI for illustrative purposes only.

Hemo Organic Limited has accepted the resignation of Yukta Prakash Patel from her role as Company Secretary and Compliance Officer. The departure becomes effective immediately following the closure of business hours on September 19, 2026.

The company disclosed the change to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing references SEBI Circular No. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding detailed disclosures for such changes.

Resignation Details

Yukta Prakash Patel, who holds ICSI Membership No. A76482, tendered her resignation citing personal reasons. She confirmed in her resignation letter that there are no other material reasons for her departure beyond those stated.

Particulars	Details
Name	Yukta Prakash Patel
Designation	Company Secretary and Compliance Officer
Reason	Personal reasons
Effective Date	September 19, 2026

The Board of Directors accepted the resignation on the same date. Vishwambar Kameshwar Singh, Managing Director, authorized the disclosure on behalf of the company. The firm will proceed with filing the necessary forms with the Ministry of Corporate Affairs.

Will Hemo Organic Limited appoint an interim Company Secretary to ensure regulatory compliance during the transition period?

How might this leadership change impact the company's ongoing compliance with SEBI's Listing Obligations and Disclosure Requirements?

Are there any pending regulatory filings or audits that could be affected by the immediate departure of the Compliance Officer?

Hemo Organic schedules board meeting to consider fund raising via QIP

1 min read | Published on 19 Sept 2026, 06:49 PM |Updated on 19 Sept 2026, 06:49 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Board meeting scheduled for September 23, 2026, to discuss fund raising options
Proposal includes equity shares or convertible securities via QIP or preferential allotment
Trading window closed from September 19, 2026, until 48 hours post-meeting
Approval requires regulatory consent and member approval

*this image is generated using AI for illustrative purposes only.

Hemo Organic Limited will hold a board meeting on September 23, 2026, to consider proposals for raising funds through various permissible modes. The company is exploring options including qualified institutions placement and preferential allotment.

The board aims to approve the issuance of equity shares or convertible securities for cash or other consideration. This move seeks to secure capital through mechanisms such as share swaps or rights issues, subject to necessary regulatory approvals.

Fund Raising Proposal Details

The agenda includes considering the issuance of equity shares and convertible securities, including convertible warrants. The company may raise funds in one or more tranches through:

Preferential allotment
Private placement
Qualified institutions placement (QIP)
Rights issue
Further public issue

These actions require statutory approvals and consent from members. The board will also consider any ancillary actions required for such fund raising.

Trading Window Closure

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window remains closed. This restriction starts from business closing hours on September 19, 2026, and continues until 48 hours after the conclusion of the board meeting.

The disclosure was made pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ayush Dharmendrabhai Jasani, Chairman and Additional Director, signed the intimation letter addressed to BSE Limited.

What specific strategic initiatives or operational expansions is Hemo Organic planning to fund with the proceeds from this capital raise?

How might the chosen fundraising instrument, such as a QIP or preferential allotment, impact existing shareholder equity and potential dilution?

Given the current market conditions for pharmaceutical and organic sector stocks, what valuation range is Hemo Organic likely targeting for these new issuances?